Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Intermittent fasting may cut cancer risk in obesity

NCT ID NCT05114798

Prevention Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This study compares time-restricted eating (eating only between 12pm-8pm) to daily calorie restriction for weight loss and colorectal cancer risk reduction in 193 obese adults aged 45-70. Participants follow their assigned diet for 6 months, then a maintenance phase for another 6 months. Researchers will measure weight, body fat, and blood markers linked to cancer risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
time-restricted eating (intermittent fasting)
What this could lead to
If it works, this could offer a simple, effective lifestyle strategy to reduce obesity and potentially lower colorectal cancer risk.
What could go wrong
This is a mid-stage behavioral study with 193 participants, so results may not apply to everyone. Adherence to the eating schedule can be challenging, and weight loss may not directly translate to cancer prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

194 people

The number who actually took part.

Started

May 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 45-70 years old, 2. BMI 30-49.99 kg/m2 3. Are up to date with CRC screening. Exclusion Criteria: 1. Have a history of renal disease, autoimmune disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery; 2. Abuse alcohol (\> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco; 3. Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on hemoglobin A1c (HbA1c) \> 9.0%; 4. Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome); 5. Have a baseline body weight \> 450 lbs (weight limitation of the DXA); 6. Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers); 7. Are not weight stable for 3 months prior to the study (weight gain or loss \> 4 kg); 8. Are unable to keep a food diary for 7 consecutive days during screening; 9. Are night shift workers; 10. Are pregnant or trying to get pregnant; 11. Are taking drugs that influence study outcomes (weight loss medications); 12. Are non-English speaking 13. Are taking anticoagulant medications or medications with endoscopic risk 14. Are taking antivirals or immunosuppressant medications 15. Don't have regular access to an email address and computer/smartphone/tablet 16. Are currently following a diet that requires fasting on a weekly basis 17. Currently eat for less than 10 hours of the day (determined by asking participants what time they start and stop eating on a usual day)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal neoplasm Intermittent Fasting Obesity obesity disorder Weight Loss colorectal cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Obesity Time-restricted eating Weight loss

Contacts and locations

Locations

  • University of Illinois at Chicago

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.